Figure 6: The typical picture of cetuximab/Erbitux®-associated skin rash, consisting of acneiform, pustular or maculopapillary hyperkeratotic follicular exanthem, preferentially affects seborrhoeic areas of skin. Concomitant dermatological treatment is indicated.